Colitis  >>  andecaliximab (GS-5745)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
andecaliximab (GS-5745) / Gilead
NCT02520284 / 2014-005217-24: Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Terminated
2/3
165
Canada, US, Europe, RoW
Andecaliximab, GS-5745, Placebo
Gilead Sciences
Ulcerative Colitis
09/16
11/16

Download Options